» Articles » PMID: 2446487

Medical Management of Malignant Pericardial Effusion by Tetracycline Sclerosis

Overview
Journal Am J Cardiol
Date 1987 Nov 15
PMID 2446487
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Fifty-eight patients with malignant pericardial effusion were seen from 1979 to 1986. A Kifa catheter was inserted into the pericardial sac and allowed to drain for 12 to 24 hours during electrocardiographic monitoring. Lidocaine hydrochloride, 100 mg, was instilled intrapericardially, followed by tetracycline hydrochloride, 500 to 1,000 mg, in 20 ml of normal saline solution. The catheter was clamped for 1 to 2 hours and then reopened. This procedure was repeated daily until the net drainage was less than 25 ml/24 hours. There were 22 male and 36 female patients (median age 58 years). The primary malignancy included lung (27 patients), breast (16 patients), stomach (3 patients), adenocarcinoma of unknown primary (7 patients), mesothelioma (2 patients) and chronic granulocytic leukemia, ovary and lymphoma (1 patient each). Fifty-six patients received 1 to 5 tetracycline instillations. In 1 patient, the catheter could not be inserted and in another, clotting occurred within the catheter before injection of tetracycline. Complications included transient atrial arrhythmias (5 patients), pain after injection (9 patients) and temperature higher than 37.5 degrees C (5 patients). One patient had a cardiac arrest during pericardiocentesis. Forty-three patients (74%) had control of their effusions for longer than 30 days (median survival 168 days, range 30 to 1,149+), and 5 patients (9%) died before 30 days without effusion. Eight patients (14%) did not achieve control. One declined further therapy after 1 instillation, and 3 died within 6 days with progressive malignancy. One patient had persistent drainage after 3 instillations, and 3 had reaccumulation of fluid 2, 6 and 27 days after catheter removal.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Diagnosis, treatment, and management of pericardial effusion- review.

Yamani N, Abbasi A, Almas T, Mookadam F, Unzek S Ann Med Surg (Lond). 2022; 80:104142.

PMID: 35846853 PMC: 9283797. DOI: 10.1016/j.amsu.2022.104142.


Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study.

Imai H, Kaira K, Masubuchi K, Minato K Curr Oncol. 2022; 29(1):163-172.

PMID: 35049689 PMC: 8774651. DOI: 10.3390/curroncol29010015.


Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study.

Kotake M, Imai H, Kaira K, Fujisawa T, Yanagita Y, Minato K Cancer Chemother Pharmacol. 2019; 84(3):655-660.

PMID: 31250155 PMC: 6682572. DOI: 10.1007/s00280-019-03897-0.


Comparison of surgical pericardial drainage with percutaneous catheter drainage for pericardial effusion.

Saltzman A, Paz Y, Rene A, Green P, Hassanin A, Argenziano M J Invasive Cardiol. 2012; 24(11):590-3.

PMID: 23117314 PMC: 3713510.


[Treatment of malignant pericardial effusion].

Berg M, Heisel A, Ukena D, Schafers H, Schieffer H Med Klin (Munich). 2009; 92 Suppl 5:27-30.

PMID: 19479393 DOI: 10.1007/BF03041976.